PDCD1 and lung carcinoma: It enhances CD8+ T-cell cytotoxicity and synergizes with anti–PD-1 therapy in colorectal and lung cancer models, partly through HDAC inhibition, regulation of T-cell exhaustion pathways, and modulating T cell receptor signaling [90–93].